Editorial: High qHBsAg-Is it a good or bad signal? Authors' reply

Hsin-Che Lin^{1

2}, Wen-Juei Jeng^{3

4}, Hwai-I Yang^{1

5

6

7}

Affiliations

¹ Genomics Research Center, Academia Sinica, Taipei, Taiwan.
² Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.
³ Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.
⁴ Chang Gung University College of Medicine, Taoyuan, Taiwan.
⁵ Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
⁶ Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
⁷ Biomedical Translation Research Center, Academia Sinica, Taipei, Taiwan.

Editorial

Hsin-Che Lin et al. Aliment Pharmacol Ther. 2024 Jun.

. 2024 Jun;59(12):1618-1619.

doi: 10.1111/apt.18021. Epub 2024 May 7.

Hsin-Che Lin^{1

2}, Wen-Juei Jeng^{3

4}, Hwai-I Yang^{1

5

6

7}

¹ Genomics Research Center, Academia Sinica, Taipei, Taiwan.
² Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.
³ Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.
⁴ Chang Gung University College of Medicine, Taoyuan, Taiwan.
⁵ Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
⁶ Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
⁷ Biomedical Translation Research Center, Academia Sinica, Taipei, Taiwan.

No abstract available

Comment on

Editorial: High qHBsAg-is it a good or bad signal?
Kim BK. Kim BK. Aliment Pharmacol Ther. 2024 Jun;59(12):1616-1617. doi: 10.1111/apt.17965. Epub 2024 Apr 21. Aliment Pharmacol Ther. 2024. PMID: 38643495 No abstract available.

1. Kim BK. Editorial: high qHBsAg – is it a good or bad signal? Aliment Pharmacol Ther. 2024;59:1616–1617.
1. Lin HC, Jeng WJ, Liu J, Pan MH, Lee MH, Batrla‐Utermann R, et al. Persistently high HBsAg levels during HBeAg‐seropositive stage predict lower risk of hepatocellular carcinoma in chronic hepatitis B patients. Aliment Pharmacol Ther. 2024;59:993–1002.
1. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142:1140–1149.e3.
1. Yang HI, Tseng TC, Liu J, Lee MH, Liu CJ, Su TH, et al. Incorporating serum level of hepatitis B surface antigen or omitting level of hepatitis B virus DNA does not affect calculation of risk for hepatocellular carcinoma in patients without cirrhosis. Clin Gastroenterol Hepatol. 2016;14:461–468.e2.
1. Choi WM, Kim GA, Choi J, Han S, Lim YS. Increasing on‐treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg‐positive chronic hepatitis B. J Clin Invest. 2022;132(10):e154833. doi: 10.1172/JCI154833.